Bio-Techne Corporation logo
TECHBio-Techne Corporation

EV/Assets Ratio: 4.40x

Is the EV/Assets ratio high or low?

The EV/Assets ratio of 4.40x is 15% below its 5-year average of 5.19x, near the low end of its 5-year range (2.70x–9.85x).

As of Saturday, June 27, 2026. 22.79% above its 12-month average of 3.58x.

TECH EV/Assets Ratio

TECH EV/Assets Ratio Chart

4.40x
+34.15% 1Y
TECH EV/Assets Ratio

TECH Average EV/Assets Ratio Chart

TECH EV/Assets Ratio

TECH Current vs Average EV/Assets Ratio Chart

TECH EV/Assets Ratio Metrics

EV/ASSETS RATIO

4.40x

EV/ASSETS RATIO AVG TTM

3.58x

EV/ASSETS RATIO AVG 3Y

4.05x

EV/ASSETS RATIO AVG 5Y

4.88x

EV/ASSETS RATIO AVG 10Y

4.44x

EV/ASSETS RATIO AVG 15Y

4.01x

EV/ASSETS RATIO AVG 20Y

4.30x

CURRENT VS TTM AVG

+22.79%

CURRENT VS 3Y AVG

+8.68%

CURRENT VS 5Y AVG

-9.77%

CURRENT VS 10Y AVG

-0.92%

CURRENT VS 15Y AVG

+9.79%

CURRENT VS 20Y AVG

+2.36%

TECH Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B4.40x3.58x4.05x4.88x
Insulet Corp. (PODD)vs ›$10.96B3.88x5.89x6.05x7.36x
Baxter International Inc. (BAX)vs ›$11.38B0.96x0.90x1.04x1.31x
Molina Healthcare, Inc. (MOH)vs ›$11.79B0.59x0.53x0.93x1.07x
Charles River Laboratories International, Inc. (CRL)vs ›$10.39B1.74x1.51x1.59x1.93x
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B0.56x0.52x0.58x0.69x
Tempus AI, Inc. (TEM)vs ›$9.80B5.08x6.17x7.83x7.83x
Henry Schein, Inc. (HSIC)vs ›$9.68B1.19x1.10x1.15x1.27x
Revvity, Inc. (RVTY)vs ›$12.61B1.26x1.11x1.18x1.38x
Align Technology, Inc. (ALGN)vs ›$12.78B1.84x1.75x2.53x3.70x

EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/Assets Ratio FAQ

What is the EV/Assets ratio for Bio-Techne Corporation (TECH)?
The EV/Assets ratio for TECH stock is 4.40x.
Is Bio-Techne Corporation's EV/Assets ratio high or low?
The EV/Assets ratio of 4.40x is 15% below its 5-year average of 5.19x, near the low end of its 5-year range (2.70x–9.85x).
What is the TTM average EV/Assets ratio for Bio-Techne Corporation (TECH)?
The TTM average EV/Assets ratio for TECH stock is 3.58x.
What is the 3Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
The 3Y average EV/Assets ratio for TECH stock is 4.05x.
What is the 5Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
The 5Y average EV/Assets ratio for TECH stock is 4.88x.
What is the 10Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
The 10Y average EV/Assets ratio for TECH stock is 4.44x.
What is the 15Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
The 15Y average EV/Assets ratio for TECH stock is 4.01x.
What is the 20Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
The 20Y average EV/Assets ratio for TECH stock is 4.30x.

TECH EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-264.40x
2026-06-254.38x
2026-06-243.65x
2026-06-233.49x
2026-06-223.45x
2026-06-183.60x
2026-06-173.42x
2026-06-163.48x
2026-06-153.49x
2026-06-123.35x
2026-06-113.36x
2026-06-103.26x
2026-06-093.38x
2026-06-083.27x
2026-06-053.23x
2026-06-043.30x
2026-06-033.16x
2026-06-023.09x
2026-06-013.16x
2026-05-293.21x
2026-05-283.16x
2026-05-272.99x
2026-05-262.98x
2026-05-223.00x
2026-05-212.95x
2026-05-202.91x
2026-05-192.83x
2026-05-182.77x
2026-05-152.70x
2026-05-142.78x
2026-05-132.79x
2026-05-122.95x
2026-05-112.95x
2026-05-083.01x
2026-05-073.16x
2026-05-062.95x
2026-05-053.60x
2026-05-043.48x
2026-05-013.49x
2026-04-303.51x
2026-04-293.30x
2026-04-283.40x
2026-04-273.50x
2026-04-243.44x
2026-04-233.32x
2026-04-223.72x
2026-04-213.78x
2026-04-203.84x
2026-04-173.76x
2026-04-163.64x
2026-04-153.71x
2026-04-143.72x
2026-04-133.65x
2026-04-103.53x
2026-04-093.53x
2026-04-083.51x
2026-04-073.42x
2026-04-063.42x
2026-04-023.38x
2026-04-013.40x
2026-03-313.32x
2026-03-303.31x
2026-03-273.24x
2026-03-263.35x
2026-03-253.35x
2026-03-243.33x
2026-03-233.31x
2026-03-203.27x
2026-03-193.28x
2026-03-183.23x
2026-03-173.25x
2026-03-163.11x
2026-03-133.24x
2026-03-123.27x
2026-03-113.41x
2026-03-103.36x
2026-03-093.49x
2026-03-063.42x
2026-03-053.55x
2026-03-043.67x
2026-03-033.62x
2026-03-023.67x
2026-02-273.74x
2026-02-263.68x
2026-02-253.67x
2026-02-243.66x
2026-02-233.48x
2026-02-203.65x
2026-02-193.70x
2026-02-183.76x
2026-02-173.71x
2026-02-133.80x
2026-02-123.78x
2026-02-114.02x
2026-02-104.10x
2026-02-094.15x
2026-02-064.23x
2026-02-054.17x
2026-02-044.34x
2026-02-034.10x
2026-02-024.14x
2026-01-304.07x
2026-01-294.06x
2026-01-284.16x
2026-01-274.32x
2026-01-264.28x
2026-01-234.32x
2026-01-224.41x
2026-01-214.52x
2026-01-204.40x
2026-01-164.35x
2026-01-154.43x
2026-01-144.33x
2026-01-134.21x
2026-01-124.22x
2026-01-094.17x
2026-01-084.10x
2026-01-074.13x
2026-01-064.14x
2026-01-054.00x
2026-01-023.79x
2025-12-313.74x
2025-12-303.76x
2025-12-293.77x
2025-12-263.76x
2025-12-243.76x
2025-12-233.77x
2025-12-223.75x
2025-12-193.71x
2025-12-183.63x
2025-12-173.63x
2025-12-163.65x
2025-12-153.73x
2025-12-123.72x
2025-12-113.83x
2025-12-103.86x
2025-12-093.74x
2025-12-083.83x
2025-12-053.92x
2025-12-044.03x
2025-12-034.05x
2025-12-024.00x
2025-12-014.05x
2025-11-284.09x
2025-11-264.10x
2025-11-254.17x
2025-11-244.03x
2025-11-213.91x
2025-11-203.73x
2025-11-193.68x
2025-11-183.70x
2025-11-173.73x
2025-11-143.77x
2025-11-133.86x
2025-11-123.90x
2025-11-113.76x
2025-11-103.66x
2025-11-073.65x
2025-11-063.70x
2025-11-053.81x
2025-11-043.83x
2025-11-033.84x
2025-10-313.92x
2025-10-303.82x
2025-10-293.89x
2025-10-284.00x
2025-10-274.02x
2025-10-244.12x
2025-10-234.13x
2025-10-223.99x
2025-10-213.97x
2025-10-203.92x
2025-10-173.88x
2025-10-163.86x
2025-10-153.74x
2025-10-143.72x
2025-10-133.74x
2025-10-103.68x
2025-10-093.76x
2025-10-083.80x
2025-10-073.71x
2025-10-063.88x
2025-10-033.94x
2025-10-023.89x
2025-10-013.76x
2025-09-303.50x
2025-09-293.29x
2025-09-263.27x
2025-09-253.18x
2025-09-243.23x
2025-09-233.33x
2025-09-223.34x
2025-09-193.35x
2025-09-183.34x
2025-09-173.25x
2025-09-163.26x
2025-09-153.25x
2025-09-123.23x
2025-09-113.35x
2025-09-103.21x
2025-09-093.41x
2025-09-083.41x
2025-09-053.42x
2025-09-043.33x
2025-09-033.36x
2025-09-023.36x
2025-08-293.44x
2025-08-283.42x
2025-08-273.53x
2025-08-263.57x
2025-08-253.56x
2025-08-223.59x
2025-08-213.35x
2025-08-203.37x
2025-08-193.41x
2025-08-183.31x
2025-08-153.33x
2025-08-143.34x
2025-08-133.40x
2025-08-123.28x
2025-08-113.12x
2025-08-083.14x
2025-08-073.12x
2025-08-063.10x
2025-08-053.39x
2025-08-043.41x
2025-08-013.41x
2025-07-313.40x
2025-07-303.58x
2025-07-293.59x
2025-07-283.63x
2025-07-253.64x
2025-07-243.62x
2025-07-233.43x
2025-07-223.30x
2025-07-213.13x
2025-07-183.23x
2025-07-173.31x
2025-07-163.22x
2025-07-153.20x
2025-07-143.27x
2025-07-113.36x
2025-07-103.38x
2025-07-093.27x
2025-07-083.27x
2025-07-073.20x
2025-07-033.30x
2025-07-023.30x
2025-07-013.24x
2025-06-303.20x
2025-06-273.22x
2025-06-263.28x
2025-06-253.23x
2025-06-243.11x
2025-06-233.07x
2025-06-203.11x
2025-06-183.12x
2025-06-173.08x
2025-06-163.21x
2025-06-133.14x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman